These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

538 related articles for article (PubMed ID: 11926144)

  • 1. [Estimation of efficacy of the octreotide LAR administration in the patients with somatotropinoma].
    Waśko R; Bolko P; Kostrzewski J; Horst-Sikorska W; Liebert W; Sowiński J
    Pol Arch Med Wewn; 2001 Aug; 106(2):693-8. PubMed ID: 11926144
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Short-term pre-surgical treatment with somatostatin analogues, octreotide and lanreotide, in acromegaly.
    Waśko R; Ruchała M; Sawicka J; Kotwicka M; Liebert W; Sowiński J
    J Endocrinol Invest; 2000 Jan; 23(1):12-8. PubMed ID: 10698045
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The value of an acute octreotide suppression test in predicting long-term responses to depot somatostatin analogues in patients with active acromegaly.
    Karavitaki N; Botusan I; Radian S; Coculescu M; Turner HE; Wass JA
    Clin Endocrinol (Oxf); 2005 Mar; 62(3):282-8. PubMed ID: 15730408
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparison between octreotide-LAR and lanreotide-SR in the chronic treatment of acromegaly.
    Cozzi R; Dallabonzana D; Attanasio R; Barausse M; Oppizzi G
    Eur J Endocrinol; 1999 Sep; 141(3):267-71. PubMed ID: 10474124
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and tolerability of lanreotide Autogel therapy in acromegalic patients previously treated with octreotide LAR.
    Alexopoulou O; Abrams P; Verhelst J; Poppe K; Velkeniers B; Abs R; Maiter D
    Eur J Endocrinol; 2004 Sep; 151(3):317-24. PubMed ID: 15362960
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Octreotide long-acting repeatable and lanreotide Autogel are equally effective in controlling growth hormone secretion in acromegalic patients.
    van Thiel SW; Romijn JA; Biermasz NR; Ballieux BE; Frölich M; Smit JW; Corssmit EP; Roelfsema F; Pereira AM
    Eur J Endocrinol; 2004 Apr; 150(4):489-95. PubMed ID: 15080778
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of octreotide acetate LAR and lanreotide SR in patients with acromegaly.
    Chanson P; Boerlin V; Ajzenberg C; Bachelot Y; Benito P; Bringer J; Caron P; Charbonnel B; Cortet C; Delemer B; Escobar-Jiménez F; Foubert L; Gaztambide S; Jockenhoevel F; Kuhn JM; Leclere J; Lorcy Y; Perlemuter L; Prestele H; Roger P; Rohmer V; Santen R; Sassolas G; Scherbaum WA; Schopohl J; Torres E; Varela C; Villamil F; Webb SM
    Clin Endocrinol (Oxf); 2000 Nov; 53(5):577-86. PubMed ID: 11106918
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of acromegaly with octreotide-LAR: extensive experience in a Brazilian institution.
    Jallad RS; Musolino NR; Salgado LR; Bronstein MD
    Clin Endocrinol (Oxf); 2005 Aug; 63(2):168-75. PubMed ID: 16060910
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Limited predictive value of an acute test with subcutaneous octreotide for long-term IGF-I normalization with Sandostatin LAR in acromegaly.
    de Herder WW; Taal HR; Uitterlinden P; Feelders RA; Janssen JA; van der Lely AJ
    Eur J Endocrinol; 2005 Jul; 153(1):67-71. PubMed ID: 15994747
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Lowered ghrelin levels in acromegaly—normalization after treatment].
    Kozakowski J; Rabijewski M; Zgliczyński W
    Endokrynol Pol; 2005; 56(6):862-70. PubMed ID: 16821203
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term effects of depot long-acting somatostatin analog octreotide on hormone levels and tumor mass in acromegaly.
    Colao A; Ferone D; Marzullo P; Cappabianca P; Cirillo S; Boerlin V; Lancranjan I; Lombardi G
    J Clin Endocrinol Metab; 2001 Jun; 86(6):2779-86. PubMed ID: 11397887
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimal dosage interval for depot somatostatin analogue therapy in acromegaly requires individual titration.
    Jenkins PJ; Akker S; Chew SL; Besser GM; Monson JP; Grossman AB
    Clin Endocrinol (Oxf); 2000 Dec; 53(6):719-24. PubMed ID: 11155094
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-acting somatostatin analog therapy of acromegaly: a meta-analysis.
    Freda PU; Katznelson L; van der Lely AJ; Reyes CM; Zhao S; Rabinowitz D
    J Clin Endocrinol Metab; 2005 Aug; 90(8):4465-73. PubMed ID: 15886238
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Comparison between integrated 24-hour concentrations of growth hormone, insulin-like growth factor I and prolactin in acromegalic patients treated with octreotide and patients treated with octreotide LAR].
    Esposito V; Esposito D; Lo Iudice G
    Minerva Endocrinol; 2001 Dec; 26(4):289-92. PubMed ID: 11782718
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term effects of lanreotide SR and octreotide LAR on tumour shrinkage and GH hypersecretion in patients with previously untreated acromegaly.
    Amato G; Mazziotti G; Rotondi M; Iorio S; Doga M; Sorvillo F; Manganella G; Di Salle F; Giustina A; Carella C
    Clin Endocrinol (Oxf); 2002 Jan; 56(1):65-71. PubMed ID: 11849248
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improvement of acromegaly after octreotide LAR treatment.
    Mangupli R; Lisette A; Ivett C; Paul C; de los Ríos Victoria C; Luis CJ
    Pituitary; 2003; 6(1):29-34. PubMed ID: 14674721
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Growth hormone isoforms in acromegalic patients before and after treatment with octreotide LAR.
    Lima GA; Wu Z; Silva CM; Barbosa FR; Dias JS; Schrank Y; Strasburger CJ; Gadelha MR
    Growth Horm IGF Res; 2010 Apr; 20(2):87-92. PubMed ID: 19884028
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Novel pharmacologic therapies in acromegaly].
    Góth M; Hubina E; Kovács L; Szabolcs I
    Orv Hetil; 2002 May; 143(19 Suppl):1057-62. PubMed ID: 12063860
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comparison of lanreotide and octreotide LAR for treatment of acromegaly.
    Turner HE; Vadivale A; Keenan J; Wass JA
    Clin Endocrinol (Oxf); 1999 Sep; 51(3):275-80. PubMed ID: 10469005
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Octreotide long-acting release (LAR): a review of its use in the management of acromegaly.
    McKeage K; Cheer S; Wagstaff AJ
    Drugs; 2003; 63(22):2473-99. PubMed ID: 14609359
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.